FDA Advisory Committee Recommends 6 Peptides for 503A Compounding: What It Means

In late July 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend that six peptides — BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax — be added to the Section 503A Bulks List. The same meeting recommended against adding emideltide.

This is a regulatory update worth tracking if you work with research peptides, because the 503A Bulks List determines which bulk substances compounding pharmacies can use — and these are among the most-studied peptides in the research space.

What happened

Over two days (July 23–24, 2026), PCAC reviewed seven peptide-related bulk substances:

• Day 1 (July 23): majority votes in favor of BPC-157, KPV, TB-500 and MOTS-c
• Day 2 (July 24): majority votes in favor of Epitalon and Semax; against Emideltide

The votes were close on some substances, and the FDA staff briefing documents had raised safety and efficacy questions beforehand — the committee’s recommendations are advisory, not binding.

Vote tallies, exactly

• BPC-157 — 8 : 6, one abstention, overruling the staff’s negative preliminary assessment
• KPV — 8 : 6 · TB-500 — 8 : 6
• MOTS-c — 7 : 5 · Epitalon — 7 : 4, one abstention · Semax — majority in favor
• Emideltide — rejected — the only substance voted down

The margins matter: every one of these was a narrow recommendation, not an endorsement, and the April 2026 removal of all six (plus five more peptides) from the Category 2 safety-risk list is the precondition that put them on this agenda at all. Full chronology: 2026 peptide regulatory timeline.

What happens next

The recommendations now move to the FDA, which is not bound to follow them. Final inclusion on the 503A Bulks List requires rulemaking. Notably, HHS Secretary Robert F. Kennedy Jr. has publicly supported the compounding-peptide direction, which is why the July vote is being watched closely by the research and pharmacy communities.

Why it matters for research supply

The six recommended peptides are core research compounds:

• BPC-157 — the gastric pentadecapeptide studied in tissue-repair and angiogenesis research
• KPV — the anti-inflammatory α-MSH fragment
• TB-500 — the thymosin β4 fragment in actin-binding and repair research
• MOTS-c — the mitochondrial-derived metabolic peptide
• Epithalon — the pineal tetrapeptide in telomere research
• Semax — the ACTH 4-10 cognitive peptide

Research-use framing

None of this changes the research-use status of these compounds: they remain investigational materials for laboratory study, supplied as lyophilized research peptides with batch COA documentation, not as approved drugs. What the regulatory movement does is signal sustained institutional interest in the same compounds the research community has been studying for years.

See the individual product pages for CAS, purity and full specifications. For reconstitution math, the peptide reconstitution calculator covers the liquid side.

For laboratory research use only. Not medical advice.